References
- CharraBCalemardERuffetMSurvival as an index of adequacy of dialysisKidney Int19924115128612911614043
- FoleyRNParfreyPSHarnettJDKentGMMurrayDCBarrePEImpact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal diseaseKidney Int199649137913858731103
- BrewsterUCSetaroJFPerazellaMAThe renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease statesAm J Med Sci2003326152412861121
- SuzukiHKannoYSugaharaSEffect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trialAm J Kidney Dis200852350150618653268
- BergerAKDuvalSKrumholzHMAspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarctionJ Am Coll Cardiol200342220120812875751
- KilpatrickRDMcAllisterCJKovesdyCPDeroseSFKoppleJDKalantar-ZadehKAssociation between serum lipids and survival in hemodialysis patients and impact of raceJ Am Soc Nephrol200718129330317167113
- ShojiTMasakaneIWatanabeYIsekiKTsubakiharaYElevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patientsClin J Am Soc Nephrol2011651112112021511840
- AgarwalRAlborziPSatyanSLightRPDry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trialHypertension200953350050719153263
- McCulloughPASandbergKRYeeJHudsonMPMortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal diseaseJ Renin Angiotensin Aldosterone Syst20023318819112563570
- TakahashiATakaseHToriyamaTCandesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis – a randomized studyNephrol Dial Transplant20062192507251216766543
- K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patientsAm J Kidney Dis2005454 Suppl 3S1S153
- RicksJMolnarMZKovesdyCPGlycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort studyDiabetes201261370871522315308
- ShinoharaKShojiTEmotoMInsulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal diseaseJ Am Soc Nephrol20021371894190012089386
- SpagnoliLGBonannoESangiorgiGMaurielloARole of inflammation in atherosclerosisJ Nucl Med200748111800181517942804
- OomichiTEmotoMTabataTImpact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational studyDiabetes Care20062971496150016801568
- Kalantar-ZadehKKoppleJDRegidorDLA1C and survival in maintenance hemodialysis patientsDiabetes Care20073051049105517337501
- AronsonDRayfieldEJHow hyperglycemia promotes atherosclerosis: molecular mechanismsCardiovasc Diabetol20021112119059
- KintscherUBramlagePPaarWDThoenesMUngerTIrbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patientsCardiovasc Diabetol200761217407587
- ParhoferKGMünzelFKreklerMEffect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational studyCardiovasc Diabetol200763618042288
- BakrisGLPharmacological augmentation of endothelium-derived nitric oxide synthesisJ Manag Care Pharm200713Suppl 5S9S1217605505
- LocatelliFCovicAChazotCLeunissenKLuñoJYaqoobMAccorde ProgrammeHypertension and cardiovascular risk assessment in dialysis patientsNephrol Dial Transplant20041951058106815004266
- WannerCKraneVMärzWGerman Diabetes and Dialysis Study InvestigatorsAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisNew Engl J Med2005353323824816034009
- CookTDCampbellDTQuasi-Experimentation: Design and Analysis Isues for Field Settings3rd edBostonHoughton Mifflin Company1979